The metrics could lead to future clinical trials that better characterize both the natural history of the disease as well as early treatment response, the authors suggest.
Study finds GA patients with a reabsorbed PED have significant visual deficits and may not benefit from new treatments aimed at inhibiting the complement system, as the mechanism is different.